



## TransEnterix to Host Virtual Investor Day on February 23, 2021

February 10, 2021

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Feb. 10, 2021-- TransEnterix, Inc. (NYSE American:TRXC), a medical device company that is digitizing the interface between the surgeon and the patient to improve minimally invasive surgery, today announced that it will host a virtual Investor Day on February 23, 2021, beginning at 11:00am Eastern Time.

"We are excited to provide an update on Senhance, including a deep dive into the technology and how we are positioning the system in Digital Laparoscopy. In addition, we will be providing updates on our corporate strategy and market opportunity," said Anthony Fernando, President and Chief Executive Officer of TransEnterix. "The company made tremendous progress during 2020, and we look forward to sharing surgeons' experiences with the Senhance Surgical System and where we see the future of Digital Laparoscopy going."

The Investor Day will be broadcast via a live video webcast, which will be available at the investor relations page of the Company's website. To register for the event in advance, please use the following link: [REGISTER](#).

Interested parties unable to watch the live webcast will be able to view and listen to an archived copy of the webcast, which will be available on <http://ir.transenterix.com/events.cfm> following the conclusion of the event.

### About TransEnterix

At TransEnterix, Inc., we are digitizing the interface between the surgeon and the patient to improve minimally invasive surgery (MIS) through a new category of care called Digital Laparoscopy. Digitizing the interface enables the use of advanced capabilities like augmented intelligence, connectivity and robotics in laparoscopy, and allows us to address the current clinical, cognitive and economic shortcomings in surgery. The system features the first machine vision system for use in robotic surgery which is powered by the new Intelligent Surgical Unit™ (ISU™) that enables augmented intelligence in surgery. The Senhance® Surgical System brings the benefits of Digital Laparoscopy to patients around the world while staying true to the principles of value-based healthcare. Learn more about Digital Laparoscopy with the Senhance Surgical System here: <https://Senhance.com/>. Now available for sale in the US, the EU, Japan, Russia, and select other countries. For a complete list of indications for use, please visit: <https://www.transenterix.com/indications-for-use/>.

### Forward-Looking Statements

This press release includes statements relating to the Company's Investor Day on February 23, 2021, including the Company's updates on its vision for the Senhance Surgical System, including its technology, corporate strategy and market opportunity. These statements and other statements regarding our future plans and goals constitute "forward looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and are intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. Such statements are subject to risks and uncertainties that are often difficult to predict, are beyond our control and which may cause results to differ materially from expectations and include where the Company sees the future of Digital Laparoscopy going. For a discussion of the risks and uncertainties associated with TransEnterix's business, please review our filings with the Securities and Exchange Commission (SEC), including our Annual Report on Form 10-K for the year ended December 31, 2019, filed with the SEC on March 16, 2020 and our other filings we make with the SEC. You are cautioned not to place undue reliance on these forward looking statements, which are based on our expectations as of the date of this press release and speak only as of the origination date of this press release. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

View source version on [businesswire.com](https://www.businesswire.com/news/home/20210210005239/en/): <https://www.businesswire.com/news/home/20210210005239/en/>

For TransEnterix, Inc.  
Investor Contact:  
Mark Klausner, +1 443-213-0501  
[invest@transenterix.com](mailto:invest@transenterix.com)  
Or  
Media Contact:  
Kristin Schaeffer  
CG Life  
+1 814-360-0660  
[kschaeffer@cglife.com](mailto:kschaeffer@cglife.com)

Source: TransEnterix, Inc.